333 related articles for article (PubMed ID: 10825417)
1. Power output of fast and slow skeletal muscles of mdx (dystrophic) and control mice after clenbuterol treatment.
Lynch GS; Hinkle RT; Faulkner JA
Exp Physiol; 2000 May; 85(3):295-9. PubMed ID: 10825417
[TBL] [Abstract][Full Text] [Related]
2. Long-term clenbuterol administration alters the isometric contractile properties of skeletal muscle from normal and dystrophin-deficient mdx mice.
Hayes A; Williams DA
Clin Exp Pharmacol Physiol; 1994 Oct; 21(10):757-65. PubMed ID: 7867226
[TBL] [Abstract][Full Text] [Related]
3. Sarcoplasmic reticulum function in slow- and fast-twitch skeletal muscles from mdx mice.
Divet A; Huchet-Cadiou C
Pflugers Arch; 2002 Aug; 444(5):634-43. PubMed ID: 12194017
[TBL] [Abstract][Full Text] [Related]
4. IGF-I treatment improves the functional properties of fast- and slow-twitch skeletal muscles from dystrophic mice.
Lynch GS; Cuffe SA; Plant DR; Gregorevic P
Neuromuscul Disord; 2001 Apr; 11(3):260-8. PubMed ID: 11297941
[TBL] [Abstract][Full Text] [Related]
5. Differentiation of original and regenerated skeletal muscle fibres in mdx dystrophic muscles.
Earnshaw JC; Kyprianou P; Krishan K; Dhoot GK
Histochem Cell Biol; 2002 Jul; 118(1):19-27. PubMed ID: 12122443
[TBL] [Abstract][Full Text] [Related]
6. Continuous testosterone administration prevents skeletal muscle atrophy and enhances resistance to fatigue in orchidectomized male mice.
Axell AM; MacLean HE; Plant DR; Harcourt LJ; Davis JA; Jimenez M; Handelsman DJ; Lynch GS; Zajac JD
Am J Physiol Endocrinol Metab; 2006 Sep; 291(3):E506-16. PubMed ID: 16621900
[TBL] [Abstract][Full Text] [Related]
7. Metabolic and physiologic characteristics of skeletal muscle determine its response to clenbuterol treatment.
Sundal S; Katoch SS; Sharma S
Indian J Biochem Biophys; 2006 Jun; 43(3):160-6. PubMed ID: 16967905
[TBL] [Abstract][Full Text] [Related]
8. Force and power output of fast and slow skeletal muscles from mdx mice 6-28 months old.
Lynch GS; Hinkle RT; Chamberlain JS; Brooks SV; Faulkner JA
J Physiol; 2001 Sep; 535(Pt 2):591-600. PubMed ID: 11533147
[TBL] [Abstract][Full Text] [Related]
9. Beneficial versus adverse effects of long-term use of clenbuterol in mdx mice.
Dupont-Versteegden EE; Katz MS; McCarter RJ
Muscle Nerve; 1995 Dec; 18(12):1447-59. PubMed ID: 7477069
[TBL] [Abstract][Full Text] [Related]
10. Time course in calpain activity and autolysis in slow and fast skeletal muscle during clenbuterol treatment.
Douillard A; Galbes O; Rossano B; Vernus B; Bonnieu A; Candau R; Py G
Can J Physiol Pharmacol; 2011 Feb; 89(2):117-25. PubMed ID: 21326343
[TBL] [Abstract][Full Text] [Related]
11. Systemic administration of IGF-I enhances oxidative status and reduces contraction-induced injury in skeletal muscles of mdx dystrophic mice.
Schertzer JD; Ryall JG; Lynch GS
Am J Physiol Endocrinol Metab; 2006 Sep; 291(3):E499-505. PubMed ID: 16621899
[TBL] [Abstract][Full Text] [Related]
12. Effects of beta 2-agonist administration and exercise on contractile activation of skeletal muscle fibers.
Lynch GS; Hayes A; Campbell SP; Williams DA
J Appl Physiol (1985); 1996 Oct; 81(4):1610-8. PubMed ID: 8904577
[TBL] [Abstract][Full Text] [Related]
13. Nuclear factor kappa-B blockade reduces skeletal muscle degeneration and enhances muscle function in Mdx mice.
Messina S; Bitto A; Aguennouz M; Minutoli L; Monici MC; Altavilla D; Squadrito F; Vita G
Exp Neurol; 2006 Mar; 198(1):234-41. PubMed ID: 16410003
[TBL] [Abstract][Full Text] [Related]
14. Year-long clenbuterol treatment of mice increases mass, but not specific force or normalized power, of skeletal muscles.
Lynch GS; Hinkle RT; Faulkner JA
Clin Exp Pharmacol Physiol; 1999 Feb; 26(2):117-20. PubMed ID: 10065331
[TBL] [Abstract][Full Text] [Related]
15. Enhanced dystrophic progression in mdx mice by exercise and beneficial effects of taurine and insulin-like growth factor-1.
De Luca A; Pierno S; Liantonio A; Cetrone M; Camerino C; Fraysse B; Mirabella M; Servidei S; Rüegg UT; Conte Camerino D
J Pharmacol Exp Ther; 2003 Jan; 304(1):453-63. PubMed ID: 12490622
[TBL] [Abstract][Full Text] [Related]
16. EDL and soleus muscles of the C57BL6J/dy2j laminin-alpha 2-deficient dystrophic mouse are not vulnerable to eccentric contractions.
Head SI; Bakker AJ; Liangas G
Exp Physiol; 2004 Sep; 89(5):531-9. PubMed ID: 15184359
[TBL] [Abstract][Full Text] [Related]
17. Effect of cyclopiazonic acid, an inhibitor of the sarcoplasmic reticulum Ca-ATPase, on skeletal muscles from normal and mdx mice.
Divet A; Lompré AM; Huchet-Cadiou C
Acta Physiol Scand; 2005 Jul; 184(3):173-86. PubMed ID: 15954985
[TBL] [Abstract][Full Text] [Related]
18. Age-related differences in regeneration of dystrophic (mdx) and normal muscle in the mouse.
Pastoret C; Sebille A
Muscle Nerve; 1995 Oct; 18(10):1147-54. PubMed ID: 7659109
[TBL] [Abstract][Full Text] [Related]
19. Low dose formoterol administration improves muscle function in dystrophic mdx mice without increasing fatigue.
Harcourt LJ; Schertzer JD; Ryall JG; Lynch GS
Neuromuscul Disord; 2007 Jan; 17(1):47-55. PubMed ID: 17134898
[TBL] [Abstract][Full Text] [Related]
20. Clenbuterol reduces degeneration of exercised or aged dystrophic (mdx) muscle.
Zeman RJ; Peng H; Danon MJ; Etlinger JD
Muscle Nerve; 2000 Apr; 23(4):521-8. PubMed ID: 10716762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
